June 29, 2026Lobbying & Public Policy, Policy & Regulation, Health Care, Policy, Regulatory, Prescription Drugs, Life Sciences, FDA Enforcement, Healthcare Innovations , Drug Development
On June 24, 2026, the Food and Drug Administration (FDA) published a notice of availability in the Federal Register requesting information and public comment on an Expedited Investigational New Drug (IND) pilot program. The proposed pilot program is part of the Trump administration’s focus on taking steps to strengthen America’s leadership in clinical research, accelerate the development of lifesaving treatments and ensure that patients have access to the most innovative therapies in the world.
Search Results
Get the latest FDA and related regulatory developments critical to the life sciences industry delivered to your inbox.
